Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.

Oncotarget - 13 Dec 2016

Brown Wells S, Akhand Saeed Salehin, Wendt Michael K

Abstract excerpt

An emerging characteristic of drug resistance in cancer is the induction of epithelial-mesenchymal transition (EMT). However, the mechanisms of EMT-mediated drug resistance remain poorly defined. Therefore, we conducted long-term treatments of human epidermal growth factor receptor-2 (Her2)-transformed breast cancer cells with either the EGFR/Her2 kinase inhibitor, Lapatinib or TGF-β, a known physiological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epithelial-Mesenchymal Transition
Share to Fibroblast Growth Factor 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyaluronan Receptors

Share to Lapatinib

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Twist-Related Protein 1

Source

Open in PubMed Open full text

Identifiers

PMID: 27825137
DOI: 10.18632/oncotarget.13117
PMCID: PMC5347779

Genes

EGFR
FGF2
FGFR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.PMID 27825137Read ↗

Rac Inhibition As A Novel Therapeutic Strategy for EGFR/HER2 Targeted Therapy Resistant Breast CancerSemantic proximity Read ↗

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family BromodomainsSemantic proximity Read ↗

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancerSemantic proximity Read ↗

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.Semantic proximity Read ↗

Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancerSemantic proximity Read ↗

Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cellsSemantic proximity Read ↗

Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.Semantic proximity Read ↗

FGFR blockade inhibits targeted therapy-tolerant persister cells in basal FGFR1 and FGF2 high expressing cancers with driver oncogenesSemantic proximity Read ↗

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer.Semantic proximity Read ↗

Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast CancerSemantic proximity Read ↗

Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancersSemantic proximity Read ↗

Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.